Zhou Kai-Yu, Jin Hang-Huang, Bai Zhi-Qiang, Liu Chi-Bo
Department of Neurosurgery, Taizhou Municipal Hospital, Taizhou Medical College, Taizhou, China.
Asian Pac J Cancer Prev. 2012;13(8):4093-5. doi: 10.7314/apjcp.2012.13.8.4093.
To determine whether pituitary adenomas can be diagnosed by identifying protein biomarkers in the serum.
We compared serum proteins from 65 pituitary adenoma patients and 90 healthy donors using proteomic fingerprint technology combining magnetic beads with matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS).
A total of 42 M/Z peaks were identified as related to pituitary adenoma (P<0.01). A diagnostic model established based on three biomarkers (3382.0, 4601.9, 9191.2) showed that the sensitivity of diagnosing pituitary adenoma was 90.0% and the specificity was 88.3%. The model was further tested by blind analysis showing that the sensitivity was 88.0% and the specificity was 83.3%.
These results suggest that proteomic fingerprint technology can be used to identify pituitary adenoma biomarkers and the model based on three biomarkers (3382.0, 4601.9, 9191.2) provides a powerful and reliable method for diagnosing pituitary adenoma.
通过鉴定血清中的蛋白质生物标志物来确定垂体腺瘤是否能够被诊断。
我们运用将磁珠与基质辅助激光解吸电离飞行时间质谱（MALDI-TOF-MS）相结合的蛋白质组指纹技术，比较了65例垂体腺瘤患者和90例健康供者的血清蛋白。
共鉴定出42个与垂体腺瘤相关的质荷比（M/Z）峰（P<0.01）。基于三种生物标志物（3382.0、4601.9、9191.2）建立的诊断模型显示，诊断垂体腺瘤的灵敏度为90.0%，特异性为88.3%。通过盲法分析对该模型进行进一步测试，结果显示灵敏度为88.0%，特异性为83.3%。
这些结果表明，蛋白质组指纹技术可用于鉴定垂体腺瘤生物标志物，基于三种生物标志物（3382.0、4601.9、9191.2）的模型为诊断垂体腺瘤提供了一种强大且可靠的方法。
